ABLYNX (ABLX)

GHENT, Belgium, 21 February 2008 - Ablynx [Euronext Brussels: ABLX],
a pioneer in the discovery and development of Nanobodies®, a novel
class of antibody-derived therapeutic proteins, will announce its
full year results for 2007 on 28 February 2008.

On this occasion, Dr Edwin Moses, CEO and Chairman of Ablynx, will
host a press conference and audio webcast call discussing the full
year results followed by a Q&A session on 28 February 2008 at 2.00 pm
CET.

Telephone and web conference details:
To participate in the call, please dial +32 (0)2 404 03 05 and enter
PIN code 55616070#, preferably 5 to 10 minutes prior to the call. The
web conference can be accessed on line through our website
http://www.ablynx.com under Investor relations/Events and
presentations.

An audio play back of the teleconference will be available during 30
days after the event and can be accessed on +32 (0)2 401 89 89 using
PIN code 229977#.

- ends -

For more information, please contact:

College Hill Life Sciences - for UK/International media enquiries:
Sue Charles, Justine Lamond, Holly Griffiths
t: +44 (0)20 7457 2020
f: +44 (0)20 7866 7900
e: ablynx@collegehill.com

Ablynx:
Dr. Edwin Moses
Chairman and CEO
t: +32 (0)9 262 00 07
m: +44 (0)7771 954 193 / +32 (0)473 39 50 68
e: edwin.moses@ablynx.com

Eva-Lotta Allan
Chief Business Officer
t: +32 (0)9 262 00 75
m: +32 (0)475 78 36 21 / +44 (0)7990 570 900
e: eva-lotta.allan@ablynx.com

Wim Ottevaere
Chief Financial Officer
t: +32 (0)9 262 00 08
e: wim.ottevaere@ablynx.com


http://hugin.info/137912/R/1193751/241562.pdf


Copyright © Hugin AS 2008. All rights reserved.